Early positive results from phase II DPX-Survivac + Keytruda in DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

IMV Inc. announced that investigators are evaluating IMV’s lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda (pembrolizumab), in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login